3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
8
Sarcoma
7
Sarcoma, Clear Cell
2
Neurofibrosarcoma
2
Nerve Sheath Neoplasms
2
Neoplasm Metastasis
2
Liposarcoma
2
Kidney Neoplasms
2
Histiocytoma, Angiomatoid Fibrous
2
Granuloma, Plasma Cell
2
Glioblastoma
2
Fibrosarcoma
2
Dermatofibrosarcoma
2
Chondrosarcoma, Extraskeletal Myxoid
2
Vascular Neoplasms
1
Solitary Fibrous Tumors
1
Solid Neoplasm
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Refractory or Recurrent Solid Tumor
1
Perivascular Epithelioid Cell Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Adipose Tissue
1
Myoepithelioma
1
Liposarcoma, Myxoid
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
spartalizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Refractory or Recurrent Solid Tumor
×
pazopanib
×
1 year
×
Clear all
NCT05210413
2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2
Active not recruiting
80 enrolled